New mRNA vaccine trial aims to boost immune attack on lung cancer
NCT ID NCT07652125
First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This early study will test a personalized mRNA vaccine (RGL-270) given together with standard immunotherapy drugs in 40 people with advanced non-small cell lung cancer. The vaccine is custom-made to target unique markers on each person's tumor. The main goal is to check safety and immune response, not yet to prove the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized neoantigen mRNA vaccine (RGL-270) combined with a PD-1/PD-L1 inhibitor
What this could lead to
If it works, this could point toward a new treatment option that helps the immune system better attack advanced lung cancer.
What could go wrong
This is a very early, small study (40 people) that hasn't started yet. It primarily looks at safety, not whether the treatment actually works. Many early-stage cancer vaccine trials do not lead to approved treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Guangdong Provincial Perople's Hospital
RECRUITINGGuangzhou, Other (Non U.s.), 510080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••